Recently, analysts issued mixed commentary on Tyra Biosciences, balancing optimism around its FGFR3 inhibitor dabogratinib and a new board appointment with renewed questions about the SURF-302 program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results